GlassScriptPhysician profile
Raj K Gupta
NPI 1861593139
$2,681.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $715 · 2021: $573 · 2022: $175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $975.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $687.61 | 2019-2022 | |
| Genzyme Corporation | $239.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.52 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $203.82 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $68.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $68.48 | 2019 | |
| Mylan Specialty L.P. | $64.52 | 2019-2021 | |
| Circassia INC. | $62.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.97 | 2019-2020 | |
| Indivior INC. | $29.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.43 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.